MX2017010062A - [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. - Google Patents
[9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.Info
- Publication number
- MX2017010062A MX2017010062A MX2017010062A MX2017010062A MX2017010062A MX 2017010062 A MX2017010062 A MX 2017010062A MX 2017010062 A MX2017010062 A MX 2017010062A MX 2017010062 A MX2017010062 A MX 2017010062A MX 2017010062 A MX2017010062 A MX 2017010062A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods relating
- compositions
- isoquinolin
- pyrido
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los compuestos que tienen una estructura de la fórmula (I), que incluyen estereoisómeros y sales y solvatos de los mismos farmacéuticamente aceptables: en donde R1 es como se definió aquí. Tales compuestos son inhibidores del transportador 2 de monoamina vesicular (VMAT2) y tienen utilidad para el tratamiento, por ejemplo, de los trastornos hipercinéticos. También se describen composiciones que contienen estos compuestos en combinación con un portador farmacéuticamente aceptable, así como los métodos relacionados con el uso en un sujeto que tenga la necesidad del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562113316P | 2015-02-06 | 2015-02-06 | |
PCT/US2016/016892 WO2016127133A1 (en) | 2015-02-06 | 2016-02-05 | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017010062A true MX2017010062A (es) | 2017-11-01 |
Family
ID=55404854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010062A MX2017010062A (es) | 2015-02-06 | 2016-02-05 | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. |
Country Status (12)
Country | Link |
---|---|
US (4) | US9714246B2 (es) |
EP (1) | EP3253752B1 (es) |
JP (1) | JP6755254B2 (es) |
KR (1) | KR102586138B1 (es) |
CN (1) | CN107438606B (es) |
AU (1) | AU2016215033B2 (es) |
CA (1) | CA2974540C (es) |
ES (1) | ES2960717T3 (es) |
IL (1) | IL253704B (es) |
MX (1) | MX2017010062A (es) |
RU (1) | RU2736509C2 (es) |
WO (1) | WO2016127133A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2936974A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
US9714246B2 (en) | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
US10065952B2 (en) | 2015-10-30 | 2018-09-04 | Neurocrine Biosciences, Inc. | Valbenazine salts and polymorphs thereof |
HRP20220621T1 (hr) | 2015-12-23 | 2022-06-24 | Neurocrine Biosciences, Inc. | Postupak sinteze za proizvodnju (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
KR20230170135A (ko) | 2017-01-27 | 2023-12-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
CN116492340A (zh) | 2017-10-10 | 2023-07-28 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
JOP20200298A1 (ar) | 2018-06-14 | 2020-11-22 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها |
CA3104693A1 (en) | 2018-08-15 | 2020-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
CA3152590A1 (en) * | 2019-09-27 | 2021-04-01 | Evan Smith | Crf receptor antagonists and methods of use |
WO2022203984A1 (en) | 2021-03-22 | 2022-09-29 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54125699A (en) * | 1978-03-17 | 1979-09-29 | Nippon Chemiphar Co Ltd | Preparation of ( ) dihydroprotoemetine |
AU2004251829B2 (en) * | 2003-06-20 | 2009-12-17 | F. Hoffmann-La Roche Ag | Hexahydropyridoisoqinolines as DPP-IV inhibitors |
PT2081929E (pt) * | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
RU2339363C2 (ru) | 2006-12-28 | 2008-11-27 | Лидия Ибрагимовна Гайсанова | Мазь "бунхо", обладающая противовоспалительным и регенерирующим действием |
CN106061506A (zh) | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
US9714246B2 (en) | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
-
2016
- 2016-02-05 US US15/017,480 patent/US9714246B2/en active Active
- 2016-02-05 WO PCT/US2016/016892 patent/WO2016127133A1/en active Application Filing
- 2016-02-05 RU RU2017130514A patent/RU2736509C2/ru active
- 2016-02-05 EP EP16705684.5A patent/EP3253752B1/en active Active
- 2016-02-05 ES ES16705684T patent/ES2960717T3/es active Active
- 2016-02-05 CA CA2974540A patent/CA2974540C/en active Active
- 2016-02-05 JP JP2017541333A patent/JP6755254B2/ja active Active
- 2016-02-05 KR KR1020177024606A patent/KR102586138B1/ko active IP Right Grant
- 2016-02-05 MX MX2017010062A patent/MX2017010062A/es active IP Right Grant
- 2016-02-05 CN CN201680008945.5A patent/CN107438606B/zh active Active
- 2016-02-05 AU AU2016215033A patent/AU2016215033B2/en active Active
-
2017
- 2017-06-19 US US15/627,145 patent/US9988382B2/en active Active
- 2017-07-27 IL IL253704A patent/IL253704B/en active IP Right Grant
-
2018
- 2018-04-30 US US15/967,187 patent/US20180273533A1/en not_active Abandoned
-
2020
- 2020-01-22 US US16/748,999 patent/US11053242B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20170113620A (ko) | 2017-10-12 |
US9988382B2 (en) | 2018-06-05 |
US11053242B2 (en) | 2021-07-06 |
US20170349586A1 (en) | 2017-12-07 |
EP3253752C0 (en) | 2023-08-16 |
KR102586138B1 (ko) | 2023-10-05 |
NZ733899A (en) | 2024-01-26 |
EP3253752A1 (en) | 2017-12-13 |
CA2974540A1 (en) | 2016-08-11 |
JP2018504437A (ja) | 2018-02-15 |
AU2016215033A1 (en) | 2017-08-10 |
IL253704A0 (en) | 2017-09-28 |
CN107438606A (zh) | 2017-12-05 |
RU2017130514A (ru) | 2019-03-07 |
US20160289226A1 (en) | 2016-10-06 |
US20200262834A1 (en) | 2020-08-20 |
EP3253752B1 (en) | 2023-08-16 |
WO2016127133A1 (en) | 2016-08-11 |
BR112017016934A2 (pt) | 2018-04-03 |
ES2960717T3 (es) | 2024-03-06 |
RU2736509C2 (ru) | 2020-11-17 |
RU2017130514A3 (es) | 2019-08-27 |
US20180273533A1 (en) | 2018-09-27 |
CA2974540C (en) | 2023-09-26 |
CN107438606B (zh) | 2020-09-18 |
US9714246B2 (en) | 2017-07-25 |
IL253704B (en) | 2021-02-28 |
JP6755254B2 (ja) | 2020-09-16 |
AU2016215033B2 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017010062A (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
MX2021000795A (es) | Compuestos heterociclicos para inhibir la actividad de shp2. | |
MX2009004910A (es) | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. | |
MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
MX2019011412A (es) | Piperidinas como inhibidores de menina covalentes. | |
MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
PH12015501813A1 (en) | Monocyclic pyridine derivative | |
MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
MX2017009824A (es) | Triazoles sustituidos y metodos relacionados a estos. | |
PH12015502429A1 (en) | Dicarboxylic acid compound | |
MX2020002824A (es) | Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia. | |
GEP20237476B (en) | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors | |
MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. | |
TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
MX2020009967A (es) | Compuesto con actividad anticancerigena. | |
MX2009013003A (es) | Derivados de piperidina-amida. | |
MX2022005201A (es) | Formulaciones de naftalimida dimerica. | |
TN2014000519A1 (en) | Pyrimidinone derivatives as antimalarial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |